Hypogammaglobulinemia and infection rates in patients with multiple sclerosis treated with ocrelizumab for up to six years: A real-world single-center study

ABSTRACT:

SUBMITTER:  

PROVIDER: S-EPMC12575957 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature